Alermax

Quick links to important sections

Alermax

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Alermax

Quick Facts

Property Description
Active ingredient Chlorphenamine maleate
Form Tablet, Syrup, Oral Solution, Injection
Pharmacological class First-Generation Antihistamine
Common use Systemic allergy symptom relief
Origin Synthetic (Alkylamine derivative)

What is Alermax and What Class Does it Belong To?

Alermax is a commercial pharmaceutical preparation containing the active substance chlorphenamine maleate, which is used to mitigate symptoms related to allergic reactions. This medication is formally classified as a first-generation antihistamine and is an established alkylamine derivative. This class of medication is used for its prompt action in allergy management.

A characteristic of this medication is its mechanism as a competitive Histamine receptor H1 antagonist. This specific structure permits it to cross the blood-brain barrier, which accounts for its inherent sedative properties, a feature that positions it within the antihistamine market compared to newer alternatives.

Composition, Forms, and General Purpose

The medication's therapeutic effect is driven by its single active ingredient, chlorphenamine maleate, which achieves systemic benefit through histamine antagonism. The drug is designed for comprehensive relief and is provided in multiple dosage forms, including standard tablets and liquid preparations such as an oral solution or syrup, simplifying administration across various patient needs.

These systemic forms are intended to alleviate a range of common allergic manifestations. By preventing histamine from binding to its target receptors, the medication serves the general purpose of reducing the physical signs of allergic response, such as persistent pruritus (itching), swelling, and excessive watery secretions.

Regulatory References

  1. NIH MedlinePlus Chlorpheniramine
  2. FDA Chlorpheniramine Drug Label

What side effects are possible with Alermax?

Possible side effects and safety information

The safety profile of Alermax, which contains chlorphenamine maleate, is structurally defined by its classification as a first-generation antihistamine, leading to common Central Nervous System (CNS) and anticholinergic effects.

CNS adverse reactions are consistently classified as Very Common, primarily presenting as sedation and drowsiness. These effects are generally noted in regulatory documents to be most pronounced at the start of treatment.

Common adverse reactions typically include manifestations of anticholinergic activity, such as dry mouth and blurred vision, as well as other effects like dizziness, fatigue, and nausea. Officially listed System-Organ Classes involved include Nervous System Disorders, Gastrointestinal Disorders, and Eye Disorders.


Serious Adverse Reactions and Population Considerations

Regulatory documentation mandates the inclusion of information regarding less frequent but clinically significant adverse reactions. These include rare systemic effects such as blood dyscrasias (e.g., Agranulocytosis) and cardiac disorders (e.g., Tachycardia and Arrhythmias).

Population-specific safety considerations are noted for older adults and children, who may experience an increased susceptibility to both anticholinergic effects and the risk of paradoxical excitation (e.g., restlessness). Safety constraints advise caution in individuals with conditions such as glaucoma or prostatic hypertrophy. Furthermore, there is an explicitly stated risk of increased sedation when the medicine is used concurrently with alcohol or other CNS depressants.

Overdose and Emergency Response

Overdose and When to Seek Help

This section describes the officially documented clinical presentations and required immediate actions for an overdose of Alermax, based on government regulatory guidance.

Documented Overdose Manifestations

An overdose of Alermax (Diphenhydramine) can affect the Central Nervous System (CNS) and the cardiovascular system. Documented overdose presentations may include severe drowsiness, agitation, delirium, hallucinations, or coma. Exaggerated anticholinergic effects are common, such as dry mouth, dilated pupils (mydriasis), urinary retention, and flushing. Serious, life-threatening outcomes include seizures, severe cardiac rhythm disturbances (arrhythmias), hypotension, and respiratory depression, which may lead to cardiac arrest or death.

Immediate Actions and Emergency Threshold

Urgent medical attention must be sought immediately in the event of a suspected overdose.

Regulatory documents explicitly state that emergency medical services or Poison Control should be contacted right away. Immediate help is required if the person who took Alermax exhibits any of the following severe signs:

  • Seizures or convulsions
  • Inability to be awakened (unresponsive)
  • Severe confusion or hallucinations
  • Difficulty breathing or collapse

Official Management: Management is primarily supportive and symptomatic. Healthcare professionals may utilize continuous observation, cardiac monitoring, and specific supportive measures, such as administering activated charcoal.

Therapeutic Uses of Alermax

What Alermax Treats: Main Uses and Benefits

Alermax is generally used in situations involving certain distressing symptoms across key domains, offering supportive symptomatic relief for allergic conditions. The medication is considered relevant for easing symptoms associated with allergic rhinitis (both seasonal and perennial) and chronic idiopathic urticaria (hives).

Alermax helps address symptom clusters that may become intense, such as sudden sneezing, runny nose, and severe itching across the eyes, nose, throat, and skin. It is applied during phases when symptoms become more noticeable, offering supportive assistance in settings marked by temporary physiological imbalance.

“The medication may assist with managing symptoms that create noticeable functional strain, such as persistent watering eyes and chronic skin irritation.”

This support helps ease the overall symptom load during difficult episodes, contributing to improved day-to-day comfort during symptomatic periods.

Quick Fact: Relevant for Easing Symptoms Related to Itching (Nasal, Ocular, and Skin)

Eligibility and Restrictions for Use

Alermax (chlorphenamine maleate) is permitted for use by adults, adolescents, and children starting at 6 years of age. Eligibility for the medicine is strictly defined by regulatory authorities based on age, concurrent medication use, and specific underlying conditions.


Populations for whom Use is Contraindicated

Absolute contraindications prohibit the use of this medicine in:

  • Patients with known hypersensitivity to chlorphenamine or any of the product's components.
  • Individuals currently using or having used a Monoamine Oxidase Inhibitor (MAOI) within the previous 14 days.

Age-Related and Condition-Specific Eligibility

Population Group Regulatory Status
Children under 6 years Use is Not Recommended.
Elderly (Geriatric) Use requires Caution.
Pregnancy/Lactation Not Recommended unless considered essential by a physician, as safety is not established.
Hepatic or Renal Impairment Use requires Caution.

Conditional use with caution is also required for patients with prostatic hypertrophy, glaucoma (raised intra-ocular pressure), or severe cardiovascular disease.

Connection to the overall eligibility profile: The regulatory documents establish clear boundaries for Alermax use by defining populations who are absolutely contraindicated due to hypersensitivity or MAOI therapy. For other groups, eligibility is made conditional, requiring use only with caution in populations such as the elderly, those with organ impairment, and those with specific pre-existing conditions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Alermax (chlorphenamine maleate) is defined by regulatory documents, focusing on pharmacodynamic and pharmacokinetic constraints that dictate specific restrictions for co-administration. These documented patterns address how the presence of other medicinal products or substances modifies the overall effect or the clearance of either medicine.


Formal Restrictions and Contraindications

Interaction Classification Interacting Substance/Class Official Interaction Statement
Contraindicated Combination Monoamine Oxidase Inhibitors (MAOIs) Co-administration is formally prohibited. This restriction extends to 14 days following the discontinuation of MAOI therapy.
Pharmacokinetic Interaction Phenytoin Chlorphenamine is documented to inhibit the hepatic metabolism of phenytoin. This leads to reduced clearance of phenytoin and an increased risk of phenytoin toxicity.

Pharmacodynamic and Substance Interactions

Concurrent use with other medicines possessing Central Nervous System (CNS) Depressant properties (such as sedatives, anxiolytics, and opioids) may result in a recognized additive CNS depression effect. Similarly, co-administration with other medications that exert anticholinergic effects (including tricyclic antidepressants) is officially documented to cause a potentiation of these effects. The ingestion of alcohol is also specified in regulatory labeling, noting that concurrent use may increase the effects of alcohol itself and contribute to the risk of additive CNS depression.

Mechanism of Action

The primary mechanism involves the molecule competitively binding to the Histamine H1 Receptor (H1R), preventing endogenously released histamine from triggering its signaling cascade. This peripheral H1R blockade suppresses the increase in vascular permeability and the stimulation of sensory nerves, resulting in the modulation of plasma exudation and the suppression of afferent sensory nerve signaling.

Due to its high lipophilicity, the molecule readily crosses the Blood-Brain Barrier (BBB), enabling occupation of H1R located in the Central Nervous System (CNS). This central action disrupts the histaminergic system’s role in promoting wakefulness and alertness, leading to a functional dampening of the CNS arousal state.

Beyond the primary target, the drug exerts a secondary antagonistic effect on Muscarinic Acetylcholine Receptors (M-receptors). This non-selective interaction modulates the cholinergic pathway, which is associated with a functional reduction in glandular secretions. However, the action is mechanistically constrained to counteracting histamine-driven signaling and does not extend to modulation of inflammatory processes driven by other mediators.

Dosage and Administration Information

Alermax, containing chlorphenamine maleate, is administered through both oral and parenteral routes, corresponding to its available forms as tablets, syrup, and solution for injection. The routes for the injection solution include intravenous, intramuscular, and subcutaneous administration.

Dosing and Frequency

The standard oral regimen for adults is 4 mg taken every 4 to 6 hours, governed by a maximum daily dose of 24 mg. For the parenteral route, the usual dose is 10 mg to 20 mg, with a maximum limit of 40 mg in any 24-hour period. These intervals and dose constraints describe the use pattern for the medication.

Administration Requirements and Adjustments

Usage instructions indicate that the medication may be taken with or without food. Administration of liquid forms requires the use of a calibrated measuring device to ensure dosage accuracy. When administering the injectable form intravenously, the injection is delivered slowly over a period of one minute.

Usage is generally short-term; continuous use is limited to a two-week period without reassessment. Furthermore, specific population guidelines exist: older adults may be subject to a lower maximum daily dose, often reduced to 12 mg. These parameters define the standard application of Alermax.

Recent Clinical Evidence

Research evidence / Overview of studies for Alermax


Research Evidence for Allergic Symptoms and Hives

Research on Alermax (chlorphenamine maleate) for symptoms of allergic rhinitis (seasonal and perennial) and hives (urticaria) primarily includes short-term Randomized Controlled Trials (RCTs) and systematic reviews of the first-generation antihistamine class. These studies were used in research exploring how symptoms change over time and were conducted in adult, adolescent, and child populations. Researchers monitored patient-reported outcomes related to nasal and ocular outcomes and physical discomfort, such as itching and wheal size. The studies focused on episodes where symptoms become more noticeable and report that findings describe patterns observed in the studies over defined, short time intervals.

For acute rhinitis, the evidence contributes to understanding symptom patterns associated with conditions characterized by fluctuating or episodic manifestations. For chronic hives, the evidence is limited for Alermax specifically, and its role was observed in this context primarily within broader drug class reviews.


Limitations and Research Gaps

Alermas was studied for its application in conditions associated with the common cold, often within fixed-dose combination products. Research describes that findings were mixed regarding other cold symptoms, such as nasal congestion, and the use of combination products means that the data provide limited insight into the contribution of Alermax alone.

As the majority of the available research involves trials assessing short-term or episodic symptom patterns, comprehensive data on long-term effects are not fully established, and there is limited information for long-term outcomes that may arise from sustained use. While Alermax was evaluated in specific populations, including children and older adults, comparative evidence is lacking in modern, head-to-head trials against the most current second-generation antihistamines. The evidence quality varies across studies, and the evidence highlights what is known — and what is still uncertain.

Key Studies & References

  1. Chlorpheniramine Maleate: FDA DailyMed Label
  2. Rhinitis 2020: A practice parameter update (AAAIAI)

Frequently Asked Questions (FAQ)

Common questions about Alermax (FAQ)


Q: Are there any delayed or long-term side effects associated with continuous use of Alermax?

The official product information primarily focuses on short-term effects. However, regulatory documents mention that rare movement disorders, such as tremors or dyskinesias (involuntary muscle movements), have been reported in some patients whose use extended over several years. Evidence concerning the long-term safety and outcomes of the medicine is considered limited.


Q: What potential side effects are specifically mentioned for children using Alermax?

According to official documents, children are described as having an increased susceptibility to neurological effects, including those that disrupt the nervous system. Specifically, there is a recognized risk of paradoxical excitation, which means that instead of drowsiness, the child may exhibit symptoms like restlessness, nervousness, or increased energy.


Q: Does Alermax interact with common over-the-counter pain relievers or cold medicines?

Regulatory guidance warns about potential combinations with other medicines that cause sedation or possess Central Nervous System (CNS) depressant effects. This is because combining them can result in an additive effect, increasing side effects like extreme drowsiness or dizziness. Official warnings describe checking for these specific pharmacological effects.


Q: What is the expected duration of action after taking one dose of Alermax?

Official pharmacokinetic data indicates that the therapeutic effects of the medicine typically reach their maximum level in about 1 to 2 hours after administration. The intended action generally lasts for approximately 4 to 6 hours after a single dose.


Q: Can Alermax be used by people who have known allergies to other types of drugs?

The product is officially contraindicated if a patient has a known hypersensitivity or allergy to the active ingredient, chlorphenamine, or any of the inactive ingredients used in the formulation. Regulatory information does not specifically address cross-reactivity with all other drug classes.


Q: Does the time of day matter when using Alermax?

The official product information does not mandate a specific time of day for administration. However, because one of the very common side effects is drowsiness or sedation, guidance often describes using the medicine in the evening. This practice helps minimize the disruption of daytime activities that may be caused by tiredness.


Q: Why is Alermax categorized as a prescription-only medication?

The classification status of this medication can vary depending on the country or region. Where it is prescription-only, this is generally due to its potential for serious drug interactions (such as with MAOIs) and its pronounced Central Nervous System effects, which often require careful management by a healthcare provider.


Q: Are there different versions of Alermax available, such as generic forms?

Yes. According to authoritative medical sources, the active substance, chlorphenamine maleate, is an established compound. It is widely available in generic form and is also sold under various other brand names besides Alermax.


Q: What are the warning signs of a serious allergic or adverse reaction to Alermax?

Warning signs of a serious allergic reaction may include symptoms like difficulty breathing or swelling of the face, lips, tongue, or throat. Regulatory documents also note rare, clinically significant effects such as changes in heart rhythm or the potential for certain blood disorders.


Q: How long does Alermax typically take to start having its intended effect?

Official pharmacokinetic data indicates that the medicine has a relatively fast onset. The intended therapeutic effects typically begin to develop quickly, usually within 30 minutes of oral administration.


Q: Does Alermax accumulate in the body over time with regular use?

Official pharmacokinetic data shows that the drug is widely distributed throughout the body after administration. The plasma half-life is estimated to be 12–15 hours, meaning that it takes time for the body to process and clear the substance.


Q: Is a slow onset of effect considered normal for Alermax?

Regulatory information describes the onset of action as relatively fast. The intended effects typically begin to develop within 30 minutes of oral administration, and a slow onset is not described as typical in the product information.


Q: Are there known concerns or warnings about Alermax and driving or operating machinery?

Yes. The product label contains specific warnings regarding activities that require mental alertness. Due to the high risk of drowsiness, dizziness, and blurred vision, regulatory documents state that the medicine can seriously affect the ability to drive or operate machinery safely.


Q: Are there any documented effects of Alermax on fertility?

Regulatory information for this medicine, which includes the dedicated 'Fertility, Pregnancy, and Lactation' section, states that there is currently no adequate data or no known effect on fertility.


Q: What steps should generally be taken if a regular dose of Alermax is forgotten?

Official instructions describe a protocol for handling a forgotten dose. The standard guidance is to take a missed dose as soon as remembered; however, if the time is almost right for the next scheduled dose, the original instructions indicate skipping the missed dose and continuing with the normal schedule.


Q: What is the physical appearance (color, shape) of the Alermax tablet/capsule?

The common 4 mg tablets are generally described in product information to be white and round. They may also have a score mark on one side to assist with splitting, if needed.

How should Alermax be stored and disposed of?

Official Storage and Disposal Requirements

The required storage and disposal conditions for Alermax (Desloratadine) are defined in regulatory labeling to maintain product stability and safety.

Storage Condition Regulatory Requirement
Temperature Store below 30 C.
Protection Keep in the original packaging to protect from moisture and light.
Child Safety Store out of the sight and reach of children.
Disposal Do not dispose of medicine via wastewater or household waste.

These official instructions mandate specific temperature constraints and protection from the environment to validate the product's shelf-life. Expired or unused Alermax must be disposed of according to local pharmaceutical waste procedures, often requiring return to a pharmacy or designated collection site.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Alermax found in:

A-Z Index: